Discussion
This pooled re-analysis of two landmark trials of heart failure
patients not previously on statins demonstrated a statistically significant
reduction in risk for MI for heart failure patients taking rosuvastatin
vs. placebo. The relative risk reduction of 19% observed for
patients with ischaemic aetiology of heart failure was statistically
significant and consistent with findings of data from large pooled
studies of non-heart failure patients. However, the magnitude of the absolute reduction in risk for MI with rosuvastatin was relatively
small given the low number of MIs in the context of their risks for
non-MI causes of death.